Beyond their glucose-lowering properties, GLP-1 RAs have gained significant attention as a therapeutic option for individuals with type 2 diabetes and obesity due to their appetite-suppressing effects (Fig. 3). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.